



Resource impact statement

Resource impact

Published: 21 April 2021

www.nice.org.uk

No significant resource impact is anticipated

We estimate that 100 people per year with metastatic Merkel cell carcinoma are eligible for treatment with avelumab.

Avelumab is recommended as an option for treating metastatic Merkel cell carcinoma in adults, only if they have had 1 or more lines of chemotherapy for metastatic disease.

We do not expect this recommendation to have a significant impact on resources: that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because the guidance covers a small population.

Further information on [implementing the guidance can be found in section 4 of the guidance](#).

[NICE has re-appraised avelumab for metastatic Merkel cell carcinoma in adults who have not had previous chemotherapy for metastatic disease](#) following a period in the Cancer Drugs Fund.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.